Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD. Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy J. Barberich. It was founded in 2009 and is headquartered in Cambridge, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 3, 2014 | Series A | $6.30M | 1 | — | — | Detail |
Oct 18, 2012 | Series Unknown | $7M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
H&Q Healthcare Investors | — | Series A |